BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 18546267)

  • 1. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
    Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
    Amin AR; Khuri FR; Chen ZG; Shin DM
    Cancer Prev Res (Phila); 2009 Jun; 2(6):538-45. PubMed ID: 19470788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
    Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin AR; Müller S; Lewis M; Sica G; Kono S; Brandes JC; Grist WJ; Moreno-Williams R; Beitler JJ; Thomas SM; Chen Z; Shin HJ; Grandis JR; Khuri FR; Chen ZG
    Clin Cancer Res; 2013 Mar; 19(5):1244-56. PubMed ID: 23422093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
    Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.
    Haque A; Rahman MA; Chen ZG; Saba NF; Khuri FR; Shin DM; Ruhul Amin AR
    Apoptosis; 2015 Jul; 20(7):986-95. PubMed ID: 25860284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
    Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB
    J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of resveratrol and green tea epigallocatechin gallate induces synergistic apoptosis and inhibits tumor growth
    Amin ARMR; Wang D; Nannapaneni S; Lamichhane R; Chen ZG; Shin DM
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33864659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway.
    Lee SH; Nam HJ; Kang HJ; Kwon HW; Lim YC
    Eur J Cancer; 2013 Oct; 49(15):3210-8. PubMed ID: 23876835
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
    Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
    Dayekh K; Johnson-Obaseki S; Corsten M; Villeneuve PJ; Sekhon HS; Weberpals JI; Dimitroulakos J
    Mol Cancer Ther; 2014 Nov; 13(11):2559-71. PubMed ID: 25189541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
    Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
    Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.
    Sah JF; Balasubramanian S; Eckert RL; Rorke EA
    J Biol Chem; 2004 Mar; 279(13):12755-62. PubMed ID: 14701854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Zhang X; Chen ZG; Choe MS; Lin Y; Sun SY; Wieand HS; Shin HJ; Chen A; Khuri FR; Shin DM
    Clin Cancer Res; 2005 Sep; 11(17):6261-9. PubMed ID: 16144930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
    Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
    Tsien CI; Nyati MK; Ahsan A; Ramanand SG; Chepeha DB; Worden FP; Helman JI; D'Silva N; Bradford CR; Wolf GT; Lawrence TS; Eisbruch A
    Head Neck; 2013 Sep; 35(9):1323-30. PubMed ID: 22907806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
    Sobhakumari A; Schickling BM; Love-Homan L; Raeburn A; Fletcher EV; Case AJ; Domann FE; Miller FJ; Simons AL
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):736-45. PubMed ID: 23917044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.